The effects of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors on changes in selected epigenetic mechanisms and DNA damage in heterozygous familial hypercholesterolaemia
2022/45/N/NZ7/01622
Keywords
Descriptors
- NZ7_014: Farmacja, farmakoterapia, farmakologia
Panel
NZ7 – Diagnostic tools, therapies and public health: public health, epidemiology, environmental health risks and occupational medicine, medical ethics, drug discovery and therapies, pharmacology
Host institution
Uniwersytet Medyczny w Łodzi, Wydział Lekarski
Voivodeship: łódzkie
Principal investigator (from the host institution)
Number of co-investigators in the project: 2
Call
PRELUDIUM 21 – announced on 2022-03-28
- Amount awarded
- 208 766 PLN
- Project start date
- 2023-03-01
- Project end date
- 2026-08-31
- Project duration
- 42 months (the same as in the proposal)
- Project status
- Pending project
Project description
Download the project description in a pdf file
Note — project descriptions were prepared by the authors of the applications themselves and placed in the system in an unchanged form.